Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 3, 2008 - Issue 2
Submit an article Journal homepage
117
Views
6
CrossRef citations to date
0
Altmetric
Review

Therapeutic potential of melatonin agonists

Daniel P Cardinali Departamento de Fisiología, Facultad de Medicina, UBA Paraguay 2155, 1121 Buenos Aires, Argentina. [email protected]
,
Seithikurippu R Pandi-Perumal Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, College of Physicians and Surgeons of Columbia University, 630 West 168th Street – Rm BB813, NY 10032, USA. [email protected]
,
Venkataramanujan Srinivasan Department of Physiology, School of Medical Sciences, University Sains Malaysia, 16150, Kubang kerian, Kelantan, Malaysia. [email protected]
,
D Warren Spence Sleep and Alertness Clinic, University Health Network, 750 Dundas Street West, Toronto, Ontario M6J-3S3, Canada. [email protected]
&
Ilya Trakht Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, College of Physicians and Surgeons of Columbia University, 630 West 168th Street – Rm BB813, NY 10032, USA. [email protected]
Pages 269-279 | Published online: 10 Jan 2014

References

  • Pandi-Perumal SR, Srinivasan V, Maestroni GJM et al. Melatonin: nature’s most versatile biological signal? FEBS J.273(13), 2813–2838 (2006).
  • Srinivasan V, Smits M, Spence W et al. Melatonin in mood disorders. World J. Biol. Psychiatry7(3), 138–151 (2006).
  • Carrillo-Vico A, Reiter RJ, Lardone PJ et al. The modulatory role of melatonin on immune responsiveness. Curr. Opin. Investig. Drugs7(5), 423–431 (2006).
  • Dopfel RP, Schulmeister K, Schernhammer ES. Nutritional and lifestyle correlates of the cancer-protective hormone melatonin. Cancer Detect. Prev.31(2), 140–148 (2007).
  • Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res.42(1), 28–42 (2007).
  • Cardinali DP, Pevet P. Basic aspects of melatonin action. Sleep Med. Rev.2(3), 175–190 (1998).
  • Reiter RJ, Tan DX. What constitutes a physiological concentration of melatonin? J. Pineal. Res.34(1), 79–80 (2003).
  • Brzezinski A. Melatonin and human reproduction: why the effect is so elusive? In: Pandi-Perumal SR, Cardinali DP (Eds). Nova Biomedical Books, NY, USA Melatonin: from Molecules to Therapy.219–225 (2007).
  • Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine27(2), 101–110 (2005).
  • Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci.17(3), 100–102 (1996).
  • von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell. Tissue Res.309(1), 151–162 (2002).
  • Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med. Rev.9(1), 51–65 (2005).
  • Buscemi N, Vandermeer B, Hooton N et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. Br. Med. J.332(7538), 385–393 (2006).
  • Brzezinski A, Vangel MG, Wurtman RJ et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med. Rev.9(1), 41–50 (2005).
  • Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med.5(6), 523–532 (2004).
  • Lewy AJ, Emens J, Jackman A, Yuhas K. Circadian uses of melatonin in humans. Chronobiol. Int.23(1–2), 403–412 (2006).
  • Srinivasan V, Smits G, Kayumov L et al. Melatonin in circadian rhythm sleep disorders. In: Cardinali DP, Pandi-Perumal SR (Eds). Springer, NY, USA Neuroendocrine Correlates of Sleep/Wakefulness.269– 294(2006).
  • Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet346(8974), 541–544 (1995).
  • Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J. Sleep Res.16(4), 372–380 (2007).
  • Wade AG, Ford I, Crawford G et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Curr. Med. Res. Opin.23(10), 2597–2605 (2007).
  • Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am. J. Psychiatry155(8), 1119–1121 (1998).
  • Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int. Clin Psychopharmacol.21(Suppl. 1), S25–S29 (2006).
  • Pandi-Perumal SR, Trakht I, Srinivasan V et al. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J. Biol. Psychiatry (2008) (In Press).
  • Dubocovich ML. Agomelatine targets a range of major depressive disorder symptoms. Curr. Opin. Investig. Drugs7(7), 670–680 (2006).
  • Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti JM. Could agomelatine be the ideal antidepressant? Expert Rev. Neurother.6(11), 1595–1608 (2006).
  • Wurtman R. Ramelteon: a novel treatment for the treatment of insomnia. Expert. Rev. Neurother.6(7), 957–964 (2006).
  • Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug insight: the use of melatonergic agonists for the treatment of insomnia – focus on ramelteon. Nat. Clin. Pract. Neurol.3(4), 221–228 (2007).
  • Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology48(2), 301–310 (2005).
  • Browning C, Beresford I, Fraser N, Giles H. Pharmacological characterization of human recombinant melatonin MT1 and MT2 receptors. Br. J. Pharmacol.129(5), 877–886 (2000).
  • Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev.12(2), 151–180 (1991).
  • Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev.9(1), 11–24 (2005).
  • Wurtman RJ, Axelrod J. The formation, metabolism and physiologic effects of melatonin. Adv. Pharmacol.6(Pt A), 141–151 (1968).
  • Cardinali DP. Melatonin. A mammalian pineal hormone. Endocr. Rev.2(3), 327–346 (1981).
  • Klein DC. Serotonin N-acetyltransferase. A personal historical perspective. Adv. Exp. Med. Biol.460, 5–16 (1999).
  • Fukuhara C, Dirden JC, Tosini G. Photic regulation of melatonin in rat retina and the role of proteasomal proteolysis. Neuroreport12(17), 3833–3837 (2001).
  • Karolczak M, Korf HW, Stehle JH. The rhythm and blues of gene expression in the rodent pineal gland. Endocrine27(2), 89–100 (2005).
  • Gauer F, Craft CM. Circadian regulation of hydroxyindole-O-methyltransferase mRNA levels in rat pineal and retina. Brain Res.737(1–2), 99–109 (1996).
  • Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. Endocrinology91(5), 1213–1218 (1972).
  • Waldhauser F, Waldhauser M, Lieberman HR et al. Bioavailability of oral melatonin in humans. Neuroendocrinology39(4), 307–313 (1984).
  • Dawson D, Armstrong SM. Chronobiotics – drugs that shift rhythms. Pharmacol. Ther.69(1), 15–36 (1996).
  • Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep20(2), 124–131 (1997).
  • Monti JM, Cardinali DP. A critical assessment of the melatonin effect on sleep in humans. Biol. Signals Recept.9(6), 328–339 (2000).
  • Karsch FJ, Malpaux B, Wayne NL, Robinson JE. Characteristics of the melatonin signal that provide the photoperiodic code for timing seasonal reproduction in the ewe. Reprod. Nutr. Dev.28(2B), 459–472 (1988).
  • Malpaux B, Tricoire H, Mailliet F et al. Melatonin and seasonal reproduction: understanding the neuroendocrine mechanisms using the sheep as a model. Reprod. Suppl.59, 167–179 (2002).
  • Vacas MI, Cardinali DP. Diurnal changes in melatonin binding sites of hamster and rat brains. Correlations with neuroendocrine responsiveness to melatonin. Neurosci. Lett.15(2–3), 259–263 (1979).
  • Pevet P. Melatonin: from seasonal to circadian signal. J. Neuroendocrinol.15(4), 422–426 (2003).
  • Lewy AJ, Bauer VK, Ahmed S et al. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol. Int.15(1), 71–83 (1998).
  • Kennaway DJ, Wright H. Melatonin and circadian rhythms. Curr. Top. Med. Chem.2(2), 199–209 (2002).
  • Lavie P. Sleep–wake as a biological rhythm. Annu. Rev. Psychol.52, 277–303 (2001).
  • Zhdanova IV, Wurtman RJ, Regan MM et al. Melatonin treatment for age-related insomnia. J. Clin. Endocrinol. Metab.86(10), 4727–4730 (2001).
  • Skene DJ, Lockley SW, Arendt J. Melatonin in circadian sleep disorders in the blind. Biol. Signals Recept.8(1–2), 90–95 (1999).
  • Cardinali DP. A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinol. Lett.23, 55–60 (2002).
  • Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer’s disease. Neuroendocrinol. Lett.23(Suppl. 1), 20–23 (2002).
  • Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Jet lag: therapeutic use of melatonin and possible application of melatonin analogues. Travel Med. Infect. Dis. (2008) (In Press).
  • Zisapel N. Sleep and sleep disturbances: biological basis and clinical implications. Cell. Mol. Life Sci.64(10), 1174–1186 (2007).
  • Cajochen C. TAK-375 Takeda. Curr. Opin. Investig. Drugs6(1), 114–121 (2005).
  • Bellon A. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial? J. Psychiatr. Pract.12(4), 229–243 (2006).
  • Stevenson S, Bryson S, Amayke D, Hibberd M. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects.Clin. Pharmacol. Ther.75, P22 (2006).
  • Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J. Clin. Pharmacol.47(4), 485–496 (2007).
  • Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP. Melatonin and sleep in aging population. Exp. Gerontol.40(12), 911–925 (2005).
  • Cajochen C, Munch M, Knoblauch V, Blatter K, Wirz-Justice A. Age-related changes in the circadian and homeostatic regulation of human sleep. Chronobiol. Int.23(1–2), 461–474 (2006).
  • Lavie P. Melatonin: role in gating nocturnal rise in sleep propensity. J. Biol. Rhythms12(6), 657–665 (1997).
  • Roth T, Seiden D, Sainati S et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med.7(4), 312–318 (2006).
  • Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose–response study of Ramelteon in patients with chronic primary insomnia. Sleep Med.7(1), 17–24 (2006).
  • Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath.11(3), 159–164 (2007).
  • Zammit G, Erman M, Wang-Weigand S et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J. Clin. Sleep Med.3(5), 495–504 (2007).
  • Lack LC, Wright HR. Chronobiology of sleep in humans. Cell. Mol. Life Sci.64(10), 1205–1215 (2007).
  • Barion A, Zee PC. A clinical approach to circadian rhythm sleep disorders. Sleep Med.8(6), 566–577 (2007).
  • van denTop M, Buijs RM, Ruijter JM et al. Melatonin generates an outward potassium current in rat suprachiasmatic nucleus neurones in vitro independent of their circadian rhythm. Neuroscience107(1), 99–108 (2001).
  • Saper CB, Lu J, Chou TC, Gooley J. The hypothalamic integrator for circadian rhythms. Trends Neurosci.28(3), 152–157 (2005).
  • Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep–wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J. Biol. Rhythms21(6), 482–493 (2006).
  • Edgar DM, Dement WC, Fuller CA. Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J. Neurosci.13(3), 1065–1079 (1993).
  • Yukuhiro N, Kimura H, Nishikawa H et al. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res.1027(1–2), 59–66 (2004).
  • Yous S, Andrieux J, Howell HE et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J. Med. Chem.35(8), 1484–1486 (1992).
  • Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther.306(3), 954–964 (2003).
  • Conway S, Drew JE, Mowat ES et al. Chimeric melatonin MT1 and melatonin-related receptors. Identification of domains and residues participating in ligand binding and receptor activation of the melatonin mt1 receptor. J. Biol. Chem.275(27), 20602–20609 (2000).
  • Bogaards JJ, Hissink EM, Briggs M et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur. J. Pharm. Sci12(2), 117–124 (2000).
  • Reynolds CF, Kupler D. Sleep in depression. In: Williams RZ, Karacan I, Moore CA (Eds). John Wiley, NY, USA Sleep Disorders, Diagnosis and Treatment.147–164 (1988).
  • Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr. Scand. (Suppl.433), 104–115 (2007).
  • Cajochen C, Brunner DP, Krauchi K, Graw P, Wirz-Justice A. EEG and subjective sleepiness during extended wakefulness in seasonal affective disorder: circadian and homeostatic influences. Biol. Psychiatry47(7), 610–617 (2000).
  • Kupfer DJ. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur. Neuropsychopharmacol.16(Suppl. 5), S639–S643 (2006).
  • Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol.17(5), 239–247 (2002).
  • Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol.16(2), 93–100 (2006).
  • Pjrek E, Winkler D, Konstantinidis A et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl.)190(4), 575–579 (2007).
  • Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord.9(6), 628–635 (2007).
  • Quera-Salva MA, Vanier B, Chapotot F. Effect of agomelatine on the sleep EEG in patients with major depressive disorders (MDD). Eur. Neuropsychopharmacol.15(Suppl. 3), S435 (2007).
  • Salva MA, Vanier B, Laredo J et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int. J Neuropsychopharmacol.10(5), 691–696 (2007).
  • Guilleminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. Eur. Neuropsychopharmacol.15(Suppl. 3), S419 (2005).
  • Lopes MC, Quera-Salva MA, Guilleminault C. Non-REM sleep instability in patients with major depressive disorder: Subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). Sleep Med.9(1), 33–41 (2007).
  • Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry68(11), 1723–1732 (2007).
  • Boivin DB. Influence of sleep–wake and circadian rhythm disturbances in psychiatric disorders. J. Psychiatry Neurosci.25(5), 446–458 (2000).
  • Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med. Rev.8(1), 19–30 (2004).
  • Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int. Clin. Psychopharmacol.22(Suppl. 2), S9–S14 (2007).
  • Fuchs E, Simon M, Schmelting B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int. Clin. Psychopharmacol.21(Suppl. 1), S17–S20 (2006).
  • Bertaina-Anglade V, la Rochelle CD, Boyer PA, Mocaer E. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav. Pharmacol.17(8), 703–713 (2006).
  • Strauss WH, Klieser E. Psychotropic effects of ritanserin, a selective S2 antagonist: an open study. Eur. Neuropsychopharmacol.1(2), 101–105 (1991).
  • Niswender CM, Herrick-Davis K, Dilley GE et al. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology24(5), 478–491 (2001).
  • Gurevich I, Tamir H, Arango V et al. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron34(3), 349–356 (2002).
  • Iwamoto K, Kato T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci. Lett.346(3), 169–172 (2003).
  • Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int. Clin. Psychopharmacol.21(Suppl. 1), S31–S35 (2006).
  • Clayton AH. Female sexual dysfunction related to depression and antidepressant medications. Curr. Womens Health Rep.2(3), 182–187 (2002).
  • Rothschild AJ. Sexual side effects of antidepressants. J. Clin. Psychiatry61(Suppl. 11), 28–36 (2000).
  • Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry62(Suppl. 3), 10–21 (2001).
  • Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol.19(5), 271–280 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.